Infantile spasms are normally treated either with a course of Prednisolone – oral steroid – or often a course of ACTH – making the body create extra steroid. If other kinds of seizures occur there are a huge number of other anti-epileptic medications that can be tried. With this syndrome, as in all types of epilepsy, the medication’s effect on a specific child cannot be foretold in advance so they may need to try several and some children may need more than one medication at a time. Dependent on the underlying cause, surgery of the brain might also be a possibility for a small number of children. As with all children having disabilities with learning, education and therapies – physio/speech/occupational – should be scheduled for the child as this will ensure that he/she is assisted in reaching their full potential as well as live life to the fullest, however severe or mild their problems are.
SABRIL causes symptoms of peripheral neuropathy in adults. Pediatric clinical trials were not designed to assess symptoms of peripheral neuropathy , but observed incidence of symptoms based on pooled data from controlled pediatric studies appeared similar for pediatric patients on vigabatrin and placebo. In a pool of North American controlled and uncontrolled epilepsy studies, % (19/457) of SABRIL patients developed signs and/or symptoms of peripheral neuropathy. In the subset of North American placebo-controlled epilepsy trials, % (4/280) of SABRIL treated patients and no (0/188) placebo patients developed signs and/or symptoms of peripheral neuropathy. Initial manifestations of peripheral neuropathy in these trials included, in some combination, symptoms of numbness or tingling in the toes or feet, signs of reduced distal lower limb vibration or position sensation, or progressive loss of reflexes, starting at the ankles. Clinical studies in the development program were not designed to investigate peripheral neuropathy systematically and did not include nerve conduction studies, quantitative sensory testing, or skin or nerve biopsy. There is insufficient evidence to determine if development of these signs and symptoms was related to duration of SABRIL treatment, cumulative dose, or if the findings of peripheral neuropathy were completely reversible upon discontinuation of SABRIL.